397 related articles for article (PubMed ID: 32644818)
1. Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical Trial.
Sagel SD; Khan U; Heltshe SL; Clancy JP; Borowitz D; Gelfond D; Donaldson SH; Moran A; Ratjen F; VanDalfsen JM; Rowe SM
Ann Am Thorac Soc; 2021 Jan; 18(1):75-83. PubMed ID: 32644818
[No Abstract] [Full Text] [Related]
2. Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor.
Rubin JL; O'Callaghan L; Pelligra C; Konstan MW; Ward A; Ishak JK; Chandler C; Liou TG
Ther Adv Respir Dis; 2019; 13():1753466618820186. PubMed ID: 30803355
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
[TBL] [Abstract][Full Text] [Related]
4. Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.
Rowe SM; McColley SA; Rietschel E; Li X; Bell SC; Konstan MW; Marigowda G; Waltz D; Boyle MP;
Ann Am Thorac Soc; 2017 Feb; 14(2):213-219. PubMed ID: 27898234
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal changes in lung function following initiation of lumacaftor/ivacaftor combination.
Loukou I; Moustaki M; Plyta M; Douros K
J Cyst Fibros; 2020 Jul; 19(4):534-539. PubMed ID: 31676345
[TBL] [Abstract][Full Text] [Related]
6. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.
Boyle MP; Bell SC; Konstan MW; McColley SA; Rowe SM; Rietschel E; Huang X; Waltz D; Patel NR; Rodman D;
Lancet Respir Med; 2014 Jul; 2(7):527-38. PubMed ID: 24973281
[TBL] [Abstract][Full Text] [Related]
7. Lumacaftor/ivacaftor in people with cystic fibrosis with an A455E-CFTR mutation.
Berkers G; van der Meer R; Heijerman H; Beekman JM; Boj SF; Vries RGJ; van Mourik P; Doyle JR; Audhya P; Yuan ZJ; Kinnman N; van der Ent CK
J Cyst Fibros; 2021 Sep; 20(5):761-767. PubMed ID: 33249003
[TBL] [Abstract][Full Text] [Related]
8. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis.
Elborn JS; Ramsey BW; Boyle MP; Konstan MW; Huang X; Marigowda G; Waltz D; Wainwright CE;
Lancet Respir Med; 2016 Aug; 4(8):617-626. PubMed ID: 27298017
[TBL] [Abstract][Full Text] [Related]
10. First experience in Switzerland in Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease enrolled in a lumacaftor-ivacaftor therapy trial - preliminary results.
Murer C; Huber LC; Kurowski T; Hirt A; Robinson CA; Bürgi U; Benden C
Swiss Med Wkly; 2018; 148():w14593. PubMed ID: 29451946
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of lumacaftor/ivacaftor initiation in children with cystic fibrosis aged 2 through 5 years on disease progression: Interim results from an ongoing registry-based study.
Kim C; Higgins M; Liu L; Volkova N; Zolin A; Naehrlich L;
J Cyst Fibros; 2024 May; 23(3):436-442. PubMed ID: 38402082
[TBL] [Abstract][Full Text] [Related]
12. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.
Konstan MW; McKone EF; Moss RB; Marigowda G; Tian S; Waltz D; Huang X; Lubarsky B; Rubin J; Millar SJ; Pasta DJ; Mayer-Hamblett N; Goss CH; Morgan W; Sawicki GS
Lancet Respir Med; 2017 Feb; 5(2):107-118. PubMed ID: 28011037
[TBL] [Abstract][Full Text] [Related]
13. Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease.
Tong K; Barker D; France M; Burr L; Greville H; Visser S; Middleton P; Wainwright C; Dorahy D; Wark P
J Cyst Fibros; 2020 May; 19(3):415-420. PubMed ID: 31848044
[TBL] [Abstract][Full Text] [Related]
14. Lumacaftor/Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR.
Milla CE; Ratjen F; Marigowda G; Liu F; Waltz D; Rosenfeld M;
Am J Respir Crit Care Med; 2017 Apr; 195(7):912-920. PubMed ID: 27805836
[TBL] [Abstract][Full Text] [Related]
15. Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.
Bulloch MN; Hanna C; Giovane R
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1055-1072. PubMed ID: 28891346
[TBL] [Abstract][Full Text] [Related]
16. Effect of Lumacaftor/Ivacaftor on Pulmonary Exacerbation Rates in Members with Cystic Fibrosis in a Medicaid Population.
Tesell MA; Alper CJ; Bacon R; Greenwood BC; Lenz K; Jeffrey PL; Stevens K
J Manag Care Spec Pharm; 2019 Sep; 25(9):1021-1025. PubMed ID: 31456498
[TBL] [Abstract][Full Text] [Related]
17. Change in exercise capacity measured by Cardio-pulmonary Exercise Testing (CPET) in Danish people with cystic fibrosis after initiation of treatment with Lumacaftor/Ivacaftor and Tezacaftor/Ivacaftor.
Rysgaard UK; Pedersen CL; Jensen JH; Sørensen L; Philipsen LKD; Leo-Hansen C; Olesen HV
J Cyst Fibros; 2022 Sep; 21(5):844-849. PubMed ID: 35667973
[TBL] [Abstract][Full Text] [Related]
18. A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for
Rayment JH; Asfour F; Rosenfeld M; Higgins M; Liu L; Mascia M; Paz-Diaz H; Tian S; Zahigian R; McColley SA
Am J Respir Crit Care Med; 2022 Nov; 206(10):1239-1247. PubMed ID: 35771568
[No Abstract] [Full Text] [Related]
19. Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study.
Chilvers MA; Davies JC; Milla C; Tian S; Han Z; Cornell AG; Owen CA; Ratjen F
Lancet Respir Med; 2021 Jul; 9(7):721-732. PubMed ID: 33516285
[TBL] [Abstract][Full Text] [Related]
20. Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous for
Stahl M; Roehmel J; Eichinger M; Doellinger F; Naehrlich L; Kopp MV; Dittrich AM; Lee C; Sommerburg O; Tian S; Xu T; Wu P; Joshi A; Ray P; Duncan ME; Wielpütz MO; Mall MA
Ann Am Thorac Soc; 2023 Aug; 20(8):1144-1155. PubMed ID: 36943405
[No Abstract] [Full Text] [Related]
[Next] [New Search]